BRIEF-Adagio Therapeutics Inc - Will Not Be Submitting A Separate Slate Of Nominees For Election To The Board At The Annual Meeting · 2d ago
PTGX, FTCI and ADGI are among after hour movers
Gainers: DLocal Limited (DLO) +20%. Agilysys (AGYS) +14%. Intercure  (INCR) +8%. Protagonist Therapeutics (PTGX) +5%. Fossil Group (FOSL) +5%. Losers: FTC Solar (FTCI) -8%. Knightscope (KSCP) -6%. Altimmune (ALT) -5%. Adagio Therapeutics
Seekingalpha · 4d ago
Morgan Stanley Adjusts Price Target for Adagio Therapeutics to $3 From $6, Maintains Underweight Rating
MT Newswires · 4d ago
BRIEF-Third Point LLC Takes Stake In Alcoa, CSX and Mosaic; Ups In Zendesk · 5d ago
--Stifel Adjusts Adagio Therapeutics' Price Target to $5 From $9, Reiterates Hold Rating
MT Newswires · 6d ago
Adagio Therapeutics GAAP EPS of -$0.93 misses by $0.21
Adagio Therapeutics press release (NASDAQ:ADGI): Q1 GAAP EPS of -$0.93 misses by $0.21.  Cash Position: Cash and cash equivalents were $532.2 million as of March 31, 2022.
Seekingalpha · 05/13 11:55
BRIEF-Adagio Therapeutics Posts Q1 Net Loss Per Share Of $0.93 · 05/13 11:41
Adagio Therapeutics Reports Q1 Loss, Higher Operating Expenses
MT Newswires · 05/13 07:02
Adagio Pauses FDA Emergency Use Request For Its COVID-19 Therapy
Benzinga · 04/14 15:24
Adagio stock falls after pausing filing plans for COVID therapy with FDA
Adagio Therapeutics (NASDAQ:ADGI) said it was pausing the submission of an emergency use authorization (EUA) request for adintrevimab (ADG20) with the U.S. Food and Drug Administration (FDA) after the drug was seen to
Seekingalpha · 04/14 12:49
Adagio Therapeutics Provides Update On Timing Of Adintrevimab EUA Request
Adagio Therapeutics, Inc. (NASDAQ:ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases, recently announced
Benzinga · 04/14 11:47
Adagio Therapeutics Pauses EUA Request for COVID-19 Drug Candidate Adintrevimab; Shares Decline Pre-Bell
MT Newswires · 04/14 09:06
When Will Adagio Therapeutics, Inc. (NASDAQ:ADGI) Breakeven?
With the business potentially at an important milestone, we thought we'd take a closer look at Adagio Therapeutics...
Simply Wall St. · 04/07 16:09
Adagio's (ADGI) COVID-19 Antibody Meets Goals in Studies
The stock price of Adagio (ADGI) surge after it reports positive preliminary data from the phase II/III studies, which evaluate its monoclonal antibody for the prevention and treatment of COVID-19.
Zacks · 03/31 16:14
23 Stocks Moving in Thursday's Pre-Market Session
Gainers IZEA Worldwide, Inc. (NASDAQ: IZEA) rose 33.3% to $1.92 in pre-market trading after the company reported Q4 EPS results up from last year and better-than-expected sales results.
Benzinga · 03/31 10:15
The Petri Dish: Adagio says its antibody works against omicron now
Adagio Therapeutics Inc. (Nasdaq: ADGI) share prices shot up after the startup said its antibody was effective at preventing and treating Covid-19 — reducing symptomatic illness by more than one-third — even in the face of the omicron variant.
American City Business Journals · 03/31 10:00
Hot Stocks: CHWY, SDIG drop on earnings news; regional banks fall; CALM sets high; ADGI clinical data
The major U.S. equity averages finished Wednesday's session lower, halting a rally that has marked most of the past two weeks. The Nasdaq led the retreat with a decline of
Seekingalpha · 03/30 22:06
Mid-Afternoon Market Update: Dow Drops 100 Points; Adagio Therapeutics Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping 100 points on Wednesday.
Benzinga · 03/30 18:42
Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?
Investor Place · 03/30 17:41
MRNA Stock: What’s Going on With Moderna This Week?
Investor Place · 03/30 17:01
Webull provides a variety of real-time ADGI stock news. You can receive the latest news about Adagio Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ADGI
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The Company's initial focus is on the virus SARS-CoV-2, its variants and the disease caused by this virus, which is known as Coronavirus Infectious Disease (COVID-19). The Company is developing its lead product candidate, ADG20, for the treatment and prevention of coronavirus disease 2019 (COVID-19). ADG20 is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 including disease caused by variants, as either a single or combination agent. The Company is also evaluating broadly neutralizing antibodies, such as ADG10, for potential use in combination with ADG20 for COVID-19.